BieglmayerC., SzepesiT., NeunteufelW.: Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA 15.3 and carcinoembryonic antigen. Cancer Lett., 42: 199–206, 1988.
2.
BombardieriE., PizzichettaM., VeronesiP., SeregniE., BogniA., MaffioliL., Saccani JottiG., BassettoM.A., ZurridaS., CostaA.: CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur. J. Cancer, 29A(1): 144–146, 1993.
3.
GendlerS.J., SpiecerA.P., LalaniE.N., DuhigT., PeatN., BurchellS., PembertonL., BoshellM., Taylor-PapadimitriouJ.: Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis., 144: S42–47, 1991.
4.
LamerzR., LeonhardtA., EhrhartH., von LievenH.: Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. Oncodev. Biol. Med., 1: 123–136, 1980.
5.
Saccani JottiG., BombardieriE.: Circulating tumor markers in breast cancer (review). Anticancer Res., 10: 253–258, 1990.
6.
SafiF., KohlerI., RottingerE., SuhrP., BegerH.G.: Comparison of CA 15.3 and CEA in diagnosis and monitoring of breast cancer. Int. J. Biol. Markers, 4: 207–214, 1989.
7.
SeregniE., BottiC., BallabioG., BombardieriE.: Molecular characteristics and genetic control of mucins. Tumor Marker Update, 7: 1–3, 1995.
TondiniC., HayesD.F., GelmanR., HendersonI.C., KufeD.W.: Comparison of CA 15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res., 48: 4107–4112, 1988.
